Jefferies has put a ‘Hold’ rating on Zydus Lifesciences with a target price of Rs 630 after the company received approval for Clindamycin Phosphate Gel USP from the United States Food and Drug Administration (USFDA). Jefferies evaluated the 2% downside potential of the company and said that, “We value Zydus Lifesciences’ core business at 23x […]